News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ImmunoGen, Inc. (IMGN) Announces Favorable Initial Safety And Response Findings For CD38-Targeting Anticancer Compound, SAR650984


12/9/2013 10:12:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted, antibody-based anticancer therapeutics, today announced the first clinical findings with SAR650984 reported in an oral presentation at the ASH annual meeting. The data are from an ongoing Phase I trial assessing this CD38-targeting therapeutic antibody in patients with CD38-positive MM or other hematologic malignancy. SAR650984 was initially developed by ImmunoGen with the Company’s target evaluation and antibody development expertise and was licensed to Sanofi as part of a broader collaboration between the companies.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES